drugset / Trial / NCT06210919

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

NCT06210919 ↗

Phase 1 Completed 3 enrolled CellinCells
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.

Timeline

Start
2023-12-06
Primary completion
2024-12-10
Completion
2025-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TRTP-101 Cell therapy — Other

Indications